Search alternatives:
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ns decrease » _ decrease (Expand Search), we decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 ns » 100 ns (Expand Search), 10 nm (Expand Search), 10 ng (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
ns decrease » _ decrease (Expand Search), we decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 ns » 100 ns (Expand Search), 10 nm (Expand Search), 10 ng (Expand Search)
-
121
-
122
Brivanib decreases viability of PDGF-BB treated LX-2 cells.
Published 2014“…Cells showed a brivanib dose-dependent decrease in viability, with half maximal inhibitory concentration (IC<sub>50</sub>) of 16.98 µM (95% CI 13.95 µM–20.67 µM). …”
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
Decrease in cell viability by siRNA and miRNA dependent induction of DTA.
Published 2014“…<p>U251 cells were transfected with the indicated construct (50 ng) with (A) or without (B) siRNAs (10pmol). …”
-
134
-
135
-
136
-
137
-
138
-
139
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
140